Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Red blood cells + plasma refers to the combined transfusion or administration of two major blood components—red blood cells (RBCs) and plasma. This combination is not a single pharmaceutical product but rather a therapeutic approach used in clinical settings, especially for patients experiencing significant hemorrhage, trauma, or coagulopathy. Red blood cells are responsible for restoring oxygen-carrying capacity and treating anemia or acute bleeding by increasing hemoglobin levels[2][3][6]. Plasma contains essential clotting factors and proteins that help restore coagulation function in patients with deficiencies, active bleeding, or those requiring reversal of anticoagulation[2][3][4][6]. The combination is often used in massive transfusion protocols to simultaneously address both oxygen delivery (via RBCs) and hemostasis (via plasma). Both components are administered intravenously.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on red blood cells + plasma.